Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

378 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diosmin has a well established use status in improvement of the symptoms of venolymphatic insufficiency: heavy legs, pain, primo-decubitus restlessness and as complement treatment of capillary fragility.

Nevertheless, diosmin 600 mg did not benefit from a rigorous clinical study versus placebo, to establish its efficacy in the pain relief in Chronic Venous Disease (CVD).

The aim of this project led by Dr. Guex is to evaluate the efficacy and safety of diosmin 600 mg - DIOVENOR® on the painful symptoms of CVD of the lower limbs, in a multicentre, controlled, randomised, double blind, placebo-controlled, parallel-group study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI)

NCT01110512

Venous Insufficiency

UNKNOWN PHASE3

Diosmin for Treatment of Delayed-onset Muscle Soreness (DOMS)

NCT06125002

Myalgia

RECRUITING PHASE1

Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency

NCT02191254

Venous Insufficiency

COMPLETED PHASE3

Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency

NCT02191163

Venous Insufficiency

COMPLETED PHASE2

Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication

NCT00102050

Intermittent Claudication Peripheral Vascular Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Venous Disease of Lower Limbs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diosmin

Group Type EXPERIMENTAL

Diosmin

Intervention Type DRUG

tablet, 600mg, PO, 1 tab per day during 28 days

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

tablet, PO, 1 per day during 28 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diosmin

tablet, 600mg, PO, 1 tab per day during 28 days

Intervention Type DRUG

Placebo

tablet, PO, 1 per day during 28 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient, man or woman, aged 18 and over,
2. Patient presenting a C1s or C2s venous disease grade of the lower limbs
3. Patient presenting a painful venous symptomatology in the lower limbs for at least 15 days.
4. Patient suffering from venous symptomatology in one leg with a painful symptom intensity higher or equal to 30 mm (VAS= 100mm)

Exclusion Criteria

1. Patient treated by venotonic treatments or vascular protectants or assimilated dietary supplements or homeopathic treatments or diuretics within 15 days prior inclusion,
2. Patients who started treatments such as calcium inhibitors, beta-blockers, angiotensin converting enzyme inhibitors and/or vasodilators and/or vasoconstrictors within 28 days prior inclusion (for patients already taking this type of treatments, dosage should not have been changed in the 28 days prior inclusion and should not be planned to change in the course of the study),
3. Patient treated by any analgesic within 7 days prior inclusion,
4. Patient treated by an anti-inflammatory treatment within 7 days prior inclusion,
5. Patient using elastic venous compression
6. Patient presenting permanent oedema,
7. Patients presenting venous skin changes,
8. Patient whose activity in the 4 following weeks (that is to say during the study) would be different from his/her usual activities (before the study),
9. Patient suffering from a pathology generating other pains than venous pains in the lower limbs,
10. Patient with a history of lower limbs trauma responsible for sequel pains,
11. Patient with a known deep venous reflux,
12. Patient with a history of venous thromboses or thrombo-embolic diseases within the last 6 months before inclusion,
13. Patient treated with analgesics or anti-inflammatory treatments used as analgesics within 4 weeks prior inclusion
14. Patient having a known hypersensitivity to diosmin or one of the excipients
15. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption ),

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No